19
Tuesday, February 24, 2026 (2:03 PM) —
Novo Nordisk plans to reduce the U.S. List prices of its leading medications Ozempic and Wegovy – used for diabetes and weight loss, respectively – by as much as 50% beginning next year, according to the Wall Street Journal. This move impacts the official U.S. Price list and aims to improve the affordability and accessibility of these widely-used drugs, as the company responds to increasing scrutiny over medication costs and growing competition within the market.
